Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Late-stage study of COVID-19 convalescent-plasma treatment with remdesivir starts

10/08/2020 | 05:33pm EST

Oct 8 (Reuters) - A late-stage trial testing the combination of Gilead Sciences' remdesivir and a highly concentrated solution of antibodies that neutralize the COVID-19 virus has begun, the National Institutes of Health (NIH) said on Thursday.

Trial investigators believe that giving the antibody solution to COVID-19 patients at the onset of symptoms could heighten the natural antibody response to the virus, thereby reducing the risk of severe illness and death. (https://bit.ly/3iF2kJf)

Emergent BioSolutions, Grifols S.A., CSL Behring and Takeda Pharmaceutical are collaborating to supply the antibody solution, NIH said.

The study, which is testing the antibody solution made up with convalescent plasma from recovered COVID-19 patients, is being conducted with hospitalized adults in the United States, Mexico and sixteen other countries.

The main goal of the trial will be to compare the health status of the patients receiving the combination treatment with those on remdesivir only, after a week.

(Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
EMERGENT BIOSOLUTIONS INC. 1.57% 80.41 Delayed Quote.49.05%
GILEAD SCIENCES, INC. -1.24% 59.5 Delayed Quote.-8.43%
GRIFOLS, S.A. 1.76% 24.24 Delayed Quote.-24.21%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.19% 3681 End-of-day quote.-15.03%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09:09aARROWHEAD PHARMACEUTICALS : Announces Closing of Agreement with Takeda
AQ
11/25TAKEDA PHARMACEUTICAL : Announcement of Making Nihon Pharmaceutical Co., Ltd. a ..
AQ
11/24TAKEDA PHARMACEUTICAL : Announcement of Making Nihon Pharmaceutical Co., Ltd. a ..
PU
11/17XOMA : Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase..
AQ
11/16TAKEDA PHARMACEUTICAL : Final Results from the Phase 3 HELP Study Open-Label Ext..
AQ
11/16Japan shares close at 29-year high on GDP rebound, vaccine race
RE
11/15Vaccine optimism, GDP data boost Japan stocks to 29-year high
RE
11/13TAKEDA PHARMACEUTICAL : Final Results from the Phase 3 HELP Study™ Open-La..
BU
11/09TAKEDA PHARMACEUTICAL : to Highlight Research Commitment in Bleeding Disorders a..
BU
11/05Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO
RE
More news
Financials
Sales 2021 3 239 B 31 066 M 31 066 M
Net income 2021 187 B 1 798 M 1 798 M
Net Debt 2021 3 859 B 37 010 M 37 010 M
P/E ratio 2021 36,6x
Yield 2021 4,89%
Capitalization 5 755 B 55 129 M 55 188 M
EV / Sales 2021 2,97x
EV / Sales 2022 2,76x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 5 297,86 JPY
Last Close Price 3 681,00 JPY
Spread / Highest target 76,6%
Spread / Average Target 43,9%
Spread / Lowest Target 11,4%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-15.03%55 234
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555